CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial

Stock Information for Cytodyn Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cytodyn Inc

CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development
CytoDyn Announces Abstract that Highlights Leronlimab's Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques
CytoDyn Announces Preliminary Findings in Study with SMC Laboratories
September 2024 Letter to Shareholders
CytoDyn Engages Leading CRO For Phase II Inflammation Trial
CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer
CytoDyn Announces Settlement with Amarex Clinical Research LLC
CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.